{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:59:14Z","timestamp":1787857154048,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The prognosis for patients with small cell lung cancer (SCLC), who develop liver metastases (LM) is extremely poor, and treatment options are limited. This study aimed to evaluate the efficacy and safety of hepatic arterial infusion (HAI) chemotherapy combined with systemic chemotherapy for patients diagnosed with LM-SCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subject and Methods:<\/jats:title>\n                    <jats:p>From January 2019 to December 2023, HAI catheter systems were implanted in 15 patients with LM-SCLC, guided by digital subtraction angiography. All patients received systemic chemotherapy in combination with HAI using gemcitabine and floxuridine (FUDR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The overall response rate for intrahepatic lesions was 66.7%, including one patient (6.7%) with a complete response and nine (60.0%) with a partial response. Additionally, the median overall survival (mOS) was 13 months (95% confidence interval, 11.4\u201314.6 months). Notably, none of the patients experienced grade 4 adverse effects. However, the grade 3 adverse effects included leukopenia and neutropenia, which were well tolerated by all the patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>HAI of gemcitabine and FUDR, alongside systemic chemotherapy, may serve as an effective treatment strategy for achieving a high local response and prolonging mOS in patients with LM-SCLC, while also being associated with a relatively low incidence of adverse effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1171_25","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:00:41Z","timestamp":1767189641000},"page":"1147-1152","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Hepatic artery infusion chemotherapy for liver metastases in small cell lung cancer"],"prefix":"10.4103","volume":"21","author":[{"given":"Ruoyu","family":"Deng","sequence":"first","affiliation":[{"name":"Department of Oncology, Qujing Central Hospital of Yunnan Province\/The Qujing Affiliated Hospital of Kunming Medical University, Qujing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qujing Central Hospital of Yunnan Province\/The Qujing Affiliated Hospital of Kunming Medical University, Qujing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Mu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qujing Central Hospital of Yunnan Province\/The Qujing Affiliated Hospital of Kunming Medical University, Qujing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyu","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qujing Central Hospital of Yunnan Province\/The Qujing Affiliated Hospital of Kunming Medical University, Qujing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qujing Central Hospital of Yunnan Province\/The Qujing Affiliated Hospital of Kunming Medical University, Qujing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Qujing Central Hospital of Yunnan Province\/The Qujing Affiliated Hospital of Kunming Medical University, Qujing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"R1-20260102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s10555-024-10220-8","article-title":"Small cell lung cancer with liver metastases:From underlying mechanisms to treatment strategies","volume":"44","author":"Fan","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"R2-20260102","doi-asserted-by":"crossref","first-page":"924","DOI":"10.4103\/jcrt.jcrt_251_25","article-title":"Precision treatment patterns and prognostic analysis:A retrospective study of small-cell lung cancer","volume":"21","author":"Wang","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R3-20260102","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R4-20260102","first-page":"620","article-title":"Clinical insights into small cell lung cancer:Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R5-20260102","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-021-00261-6","article-title":"Liver metastases","volume":"7","author":"Tsilimigras","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R6-20260102","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer:The ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"Jama"},{"key":"R7-20260102","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1):A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"key":"R8-20260102","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.18632\/aging.205035","article-title":"Impact of liver metastases status on survival outcomes of first-line immunotherapy in extensive stage small cell lung cancer:A systematic review and meta-analysis","volume":"15","author":"Lin","year":"2023","journal-title":"Aging (Albany NY)"},{"key":"R9-20260102","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"R10-20260102","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1200\/JCO.21.01881","article-title":"Extensive-stage small-cell lung cancer:First-line and second-line treatment options","volume":"40","author":"Zugazagoitia","year":"2022","journal-title":"J Clin Oncol"},{"key":"R11-20260102","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.26270","article-title":"Safety and feasibility of initiating a hepatic artery infusion pump chemotherapy program for unresectable colorectal liver metastases:A multicenter, retrospective cohort study","volume":"123","author":"Muaddi","year":"2021","journal-title":"J Surg Oncol"},{"key":"R12-20260102","doi-asserted-by":"crossref","first-page":"15330338211051552","DOI":"10.1177\/15330338211051552","article-title":"Hepatic artery infusion pump combined with systemic chemotherapy for patients with liver metastases from breast carcinoma","volume":"20","author":"Shi","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"R13-20260102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10585-019-10015-0","article-title":"Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis","volume":"37","author":"Peng","year":"2020","journal-title":"Clin Exp Metastasis"},{"key":"R14-20260102","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1007\/s12094-015-1317-8","article-title":"Hepatic arterial infusion plus systemic chemotherapy as third-line or later treatment in colorectal liver metastases","volume":"17","author":"Qiang","year":"2015","journal-title":"Clin Transl Oncol"},{"key":"R15-20260102","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R16-20260102","doi-asserted-by":"crossref","first-page":"e70256","DOI":"10.1002\/cam4.70256","article-title":"The optimal first-line therapy for extensive-stage small-cell lung cancer based on liver metastasis status:A network meta-analysis and systematic review","volume":"13","author":"Zhang","year":"2024","journal-title":"Cancer Med"},{"key":"R17-20260102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.4103\/jcrt.jcrt_192_25","article-title":"Current state and future of nonsurgical management of metastatic liver tumors","volume":"21","author":"Sharma","year":"2025","journal-title":"J Cancer Res Ther"},{"key":"R18-20260102","doi-asserted-by":"crossref","first-page":"526","DOI":"10.21037\/hbsn-21-215","article-title":"Liver metastases \u201csiphon\u201d off immunotherapy response","volume":"10","author":"Cortese","year":"2021","journal-title":"Hepatobiliary Surg Nutr"},{"key":"R19-20260102","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"R20-20260102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1158\/1078-0432.CCR-21-1193","article-title":"The liver-immunity nexus and cancer immunotherapy","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R21-20260102","doi-asserted-by":"crossref","first-page":"100003","DOI":"10.1016\/j.esmoop.2020.100003","article-title":"First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer:clinical developments and future directions","volume":"6","author":"Ortega-Franco","year":"2021","journal-title":"ESMO Open"},{"key":"R22-20260102","doi-asserted-by":"crossref","first-page":"599","DOI":"10.5582\/bst.2024.01286","article-title":"mFOLFOX-HAIC+lenvatinib+PD-1 inhibitors versus GC\/GS\/GEMOX chemotherapy as a first line therapy for advanced biliary tract cancer:A single-center retrospective cohort study","volume":"18","author":"Sun","year":"2025","journal-title":"Biosci Trends"},{"key":"R23-20260102","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/SLA.0000000000003248","article-title":"Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of KRAS mutation status in patients with resected colorectal liver metastases:A retrospective analysis of 674 patients","volume":"272","author":"Gholami","year":"2020","journal-title":"Ann Surg"},{"key":"R24-20260102","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s11154-017-9431-2","article-title":"Liver transarterial embolizations in metastatic neuroendocrine tumors","volume":"18","author":"de Mestier","year":"2017","journal-title":"Rev Endocr Metab Disord"},{"key":"R25-20260102","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0300891620952844","article-title":"Local therapies for liver metastases of rare head and neck cancers:A monoinstitutional case series","volume":"107","author":"Bergamini","year":"2021","journal-title":"Tumori"},{"key":"R26-20260102","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1055\/a-2193-0722","article-title":"Liver metastases of neuroendocrine tumors:Conventional transarterial chemoembolization and thermal ablation","volume":"196","author":"Vogl","year":"2024","journal-title":"Rofo"},{"key":"R27-20260102","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1245\/s10434-013-3275-0","article-title":"Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab","volume":"21","author":"Cercek","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"R28-20260102","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/jso.24898","article-title":"Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases:Long term results and curative potential","volume":"117","author":"Pak","year":"2018","journal-title":"J Surg Oncol"},{"key":"R29-20260102","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/SLA.0000000000000614","article-title":"Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer:Conversion to resection and long-term outcomes","volume":"261","author":"D'Angelica","year":"2015","journal-title":"Ann Surg"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1171_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:56:44Z","timestamp":1786647404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_1171_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1171_25","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"2025-06-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-19","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}